New delhi, Oct. 11 -- All is not well with pharma companies in the overseas markets, particularly the US. This is expected to reflect in lower sequential growth rates in the second quarter (Q2) of FY20.
In the first quarter (Q1), almost all domestic pharma companies registered negative growth rates in their US businesses. Competition in some of the base drugs launched earlier has been intensifying. As a result, sales volume growth has been slow.
Additionally, lack of new launches in the US market could further drag down revenue growth. "US business should be weak for almost all companies with a sharp dip in approvals in Q2, compliance issues, lack of meaningful launches and competition in base portfolios," said analysts at Emkay Global Fi...